Intelligence Platform

Patents

Browse 837 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

US 12134631

Hydrophilic linkers for antibody drug conjugates

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12127536

Humanized M-CSF mice

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12123001

Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12116622

Methods of associating genetic variants with a clinical outcome in patients suffering from

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12115216

Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12110502

Models of tauopathy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12103960

VEGF traps and mini-traps and methods for treating ocular disorders and cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12096754

Non-human animals having a humanized lymphocyte-activation gene 3

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12091440

IL2 and peptide-MHC complex fusion proteins and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12091460

Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12090193

Glucagon-like peptide 1 receptor agonists and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12089575

Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12090201

Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12091449

Anti-PfRH5 antibodies and antigen-binding fragments thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12082565

Non-human animals models of retinoschisis

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12084516

Anti-C5 antibody combinations and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12082566

Rodent animals expressing human CR1

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12083141

Treatment of hyperglycemia with solute carrier family 39 member 5 (SLC39A5) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12077587

Anti-CD8 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12077593

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12077782

Viral clearance by low pH hold

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12077570

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12070502

Process for reducing subvisible particles in a pharmaceutical formulation

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12070460

Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)